Literature DB >> 3335026

Expression of two different endogenous galactoside-binding lectins sharing sequence homology.

A Raz1, P Carmi, G Pazerini.   

Abstract

The endogenous beta-D-galactoside-binding lectins of UV-2237-IP3 fibrosarcoma cells consist of two polypeptides with molecular weights of 14,500 (L-14.5) and 34,000 (L-34). Recently we constructed complementary DNA (cDNA) libraries from these cells in the expression vector lambda gt11 and isolated and characterized cDNA clones encoding the two lectin species (A. Raz et al., Exp. Cell Res., 173: 109, 1987). We report here on the similarity in structure and gene number in genomic DNA of the fibrosarcoma cells and syngeneic normal mouse lung DNA. The expression of mRNAs hybridizing to these cDNAs was evaluated in three pairs of normal versus their transformed cell variants. Messenger RNA corresponding to the Mr 34,000 lectin was present more abundantly in the transformed cells than in their normal counterparts, while no difference was detected between the cell pairs with respect to mRNA levels corresponding to the Mr 14,500 lectin. We have established the nucleotide sequences of the two cDNA clones. The deduced amino acid sequence of L-14.5 lectin cDNA clone (L-3) is significantly homologous to the sequence of six other L-14 vertebrate galactoside binding lectins. The sequence of the Mr 34,000 lectin cDNA clone (M5) revealed that it shares a stretch of 39 amino acids with all of the L-14 galactoside binding lectins, irrespective of origin of the species, suggesting both that they are all derived from a common ancestral gene, and that this domain is necessary for similar sugar binding properties.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335026

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family.

Authors:  Z Z Su; J Lin; R Shen; P E Fisher; N I Goldstein; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Galectin-3 expression in human atherosclerotic lesions.

Authors:  M Nachtigal; Z Al-Assaad; E P Mayer; K Kim; M Monsigny
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

4.  Soluble bovine galactose-binding lectin. cDNA cloning reveals the complete amino acid sequence and an antigenic relationship with the major encephalitogenic domain of myelin basic protein.

Authors:  W M Abbott; A Mellor; Y Edwards; T Feizi
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

5.  Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs.

Authors:  G V Glinsky; V V Mossine; J E Price; D Bielenberg; V V Glinsky; H N Ananthaswamy; M S Feather
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

6.  The sequence of the mouse 14 kDa beta-galactoside-binding lectin and evidence for its synthesis on free cytoplasmic ribosomes.

Authors:  T J Wilson; M N Firth; J T Powell; F L Harrison
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

7.  Galectin-3: differential accumulation of distinct mRNAs in serum-stimulated mouse 3T3 fibroblasts.

Authors:  P G Voss; Y G Tsay; J L Wang
Journal:  Glycoconj J       Date:  1994-08       Impact factor: 2.916

8.  Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism.

Authors:  D N Cooper; S H Barondes
Journal:  J Cell Biol       Date:  1990-05       Impact factor: 10.539

9.  Galectin-1 expression in innervated and denervated skeletal muscle.

Authors:  Anna Svensson; Sven Tågerud
Journal:  Cell Mol Biol Lett       Date:  2008-10-10       Impact factor: 5.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.